Sasikiran Goud Ediga
Sasikiran Goud Ediga has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Leela Prasad Kowtharapu
Department of Chemistry School of Science GITAM Deemed to be University Hyderabad Telangana India
1 shared publication - Nandimalla Vishnu
Department of Electrical Engineering, Indian Institute of Technology, Hyderabad, 502285, India
1 shared publication - Naresh Kumar Katari
School of Chemistry & Physics, College of Agriculture, Engineering & Science, Westville Campus University of KwaZulu‐Natal Durban South Africa
1 shared publication - Rajya Lakshmi Chavakula
Department of Basic Sciences, Vishnu Institute of Technology, Bhimavaram, India
1 shared publication - Srinivasa Reddy Chinta
Novast Laboratories Ltd, Department of Quality Operations , Guangxing Rd, Free Trade Zone , NETDA, Nantong 226009, China
1 shared publication - Vaishnavi Chintala
Cambrex High Point High Point North Carolina USA
1 shared publication
Latest Publications
- 27 September 2023
- Published by Oxford University Press (OUP) in Journal of AOAC INTERNATIONAL
- Vol. 107 (1) , 31-39
Quantification of Drospirenone- and Ethinyl Estradiol-Related Impurities in a Combined Pharmaceutical Dosage Form by a Chromatography Method With a QbD Robustness Study
Background: The estimation of drugs containing drospirenone (DRSP) and ethinyl estradiol (EE), and their related impurities, in low-dose oral contraceptive drug products is an extremely challenging target. The proposed research sought to develop and validate a stability-indicating method for quantifying drug substances and their related impurities in tablet formulation. Objective: To develop and validate a simple, specific, accurate, precise, and stability-indicating reverse-phase (RP)-HPLC method for quantification of DRSP, EE, and their impurities in accordance with International Conference on Harmonisation (ICH) guidelines. Method: The separation was achieved using an Agilent Zorbax SB C18 column (4.6 mm × 250 mm, 5 µm) with a detection wavelength of 215 nm and mobile phases A (100% acetonitrile) and B (acetonitrile–water, 1 + 3, v/v) at a flow rate of 1.3 mL/min and a column temperature of 40°C. Results: The recovery study of each impurity was conducted in the range of 24 to 72 µg/mL for DRSP-related impurities and 0.2 to 0.6 µg/mL for EE-related impurities with respect to the specification limit. A linearity study was conducted over a range of 1.5 to 90 µg/mL for DRSP and DRSP-related impurities, and 0.125 to 0.75 µg/mL for EE-related impurities. A Quality by Design (QbD) study demonstrated the method’s robustness. Conclusions: As per current guidelines, a stability-indicating method has been developed for the determination of impurities in DRSP/EE film-coated tablets. A QbD-based robustness test was performed and the method was found to be robust. Highlights: An accurate, precise, stability-indicating, gradient RP-HPLC method has been developed and validated to determine DRSP, EE, and nine related impurities in tablet formulation. A QbD technique was used to establish a robustness study.
- 27 September 2023
- Published by Oxford University Press (OUP) in Journal of AOAC INTERNATIONAL
- Vol. 107 (1) , 31-39
Quantification of Drospirenone- and Ethinyl Estradiol-Related Impurities in a Combined Pharmaceutical Dosage Form by a Chromatography Method With a QbD Robustness Study
Background: The estimation of drugs containing drospirenone (DRSP) and ethinyl estradiol (EE), and their related impurities, in low-dose oral contraceptive drug products is an extremely challenging target. The proposed research sought to develop and validate a stability-indicating method for quantifying drug substances and their related impurities in tablet formulation. Objective: To develop and validate a simple, specific, accurate, precise, and stability-indicating reverse-phase (RP)-HPLC method for quantification of DRSP, EE, and their impurities in accordance with International Conference on Harmonisation (ICH) guidelines. Method: The separation was achieved using an Agilent Zorbax SB C18 column (4.6 mm × 250 mm, 5 µm) with a detection wavelength of 215 nm and mobile phases A (100% acetonitrile) and B (acetonitrile–water, 1 + 3, v/v) at a flow rate of 1.3 mL/min and a column temperature of 40°C. Results: The recovery study of each impurity was conducted in the range of 24 to 72 µg/mL for DRSP-related impurities and 0.2 to 0.6 µg/mL for EE-related impurities with respect to the specification limit. A linearity study was conducted over a range of 1.5 to 90 µg/mL for DRSP and DRSP-related impurities, and 0.125 to 0.75 µg/mL for EE-related impurities. A Quality by Design (QbD) study demonstrated the method’s robustness. Conclusions: As per current guidelines, a stability-indicating method has been developed for the determination of impurities in DRSP/EE film-coated tablets. A QbD-based robustness test was performed and the method was found to be robust. Highlights: An accurate, precise, stability-indicating, gradient RP-HPLC method has been developed and validated to determine DRSP, EE, and nine related impurities in tablet formulation. A QbD technique was used to establish a robustness study.